Ensysce Financial Statements From 2010 to 2026
| ENSCW Stock | USD 0 0 34.29% |
Check Ensysce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ensysce Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Ensysce financial statements analysis is a perfect complement when working with Ensysce Biosciences Valuation or Volatility modules.
Ensysce |
Ensysce Biosciences Company Cash Flow From Operations Analysis
Ensysce Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Ensysce Biosciences Cash Flow From Operations | (8.24 M) |
Most of Ensysce Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ensysce Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Ensysce Biosciences has (8.24 Million) in Cash Flow From Operations. This is 101.56% lower than that of the Healthcare sector and 113.18% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.85% higher than that of the company.
Ensysce Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ensysce Biosciences's current stock value. Our valuation model uses many indicators to compare Ensysce Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ensysce Biosciences competition to find correlations between indicators driving Ensysce Biosciences's intrinsic value. More Info.Ensysce Biosciences is rated below average in ebitda category among its peers. It is rated below average in net income category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ensysce Biosciences' earnings, one of the primary drivers of an investment's value.About Ensysce Biosciences Financial Statements
Ensysce Biosciences investors use historical fundamental indicators, such as Ensysce Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Ensysce Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for Ensysce Pink Sheet Analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.